Paolo Tarantino: Promising Safety and Efficacy of Camizestrant Plus CDK4/6i in SERENA1
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X about a paper by Richard D. Baird et al. published in Clinical Cancer Research:
“Safety and preliminary efficacy of camizestrant + the approved CDK4/6i in SERENA1. No clinically meaningful drug–drug interactions. Very relevant in case the 1L SERENA4 phase 3 trial is positive, which could lead to cami replacing AI as 1L ET backbone.”
Title: Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Authors: Richard D. Baird, Begoña Bermejo de las Heras, Manuel Ruiz-Borrego, Christos Vaklavas, Irene Moreno, Mafalda Oliveira, Anne Armstrong, Nicholas Turner, Jason Incorvati, Chris J. Twelves, Eva Ciruelos, Erika Hamilton, Manish R. Patel, Peter Kabos, Carmela Ciardullo, Teresa Klinowska, Justin P.O. Lindemann, Alastair M. Mathewson, Christopher J. Morrow, Andy Sykes, Jincheng Yang, Bairu Zhang, Ivan Victoria
You can read the Full Article on Clinical Cancer Research.
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023